Article Information
History
- October 16, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Manuela Di Fusco1,*,
- Mary M Moran2,
- Alejandro Cane1,
- Daniel Curcio1,
- Farid Khan2,
- Deepa Malhotra1,
- Andy Surinach3,
- Amanda Miles1,
- David Swerdlow2,
- John M McLaughlin2 and
- Jennifer L Nguyen1
- 1Pfizer Inc., New York, NY USA
- 2Pfizer Inc., Collegeville, PA, USA
- 3Genesis Research, Hoboken, NJ, USA
- ↵*Corresponding author
Manuela Di Fusco, Patient and Health Impact, Health Economics and Outcomes Research, Pfizer, Inc., New York, NY, USA, Manuela.difusco{at}pfizer.com
Posted October 16, 2021.
Evaluation of COVID-19 vaccine breakthrough infections among immunocompromised patients fully vaccinated with BNT162b2
